Moderna Inc
MRNAToday
-2.23%
5 Days
+5.48%
1 Month
+170.24%
6 Months
+177.13%
Year to Date
+393.56%
1 Year
+478.96%
Recent
Analysis
Earnings
Alnylam Pharmaceuticals Inc Stock (ALNY) Moved Up by 7.90% on Sep 2: Facts Behind the Movement
• Alnylam shares surged due to positive clinical data and favorable Wall Street analyst commentary. • Amvuttra demonstrated superior efficacy and strong clinical trial results for treating cardiomyopathy. • The company reports $3.71B in annual revenue and neutral technical indicators.
Novo Nordisk A/S Stock (NVO) Moved Up by 3.17% on Sep 2: What Signal Does It Send?
• Novo Nordisk launched its oral weight-loss treatment in Germany and Greater China. • The company continues executing its multi-billion share repurchase program supporting shareholders. • Annual revenue reached $46.70B with net profit totaling $15.48B.
Johnson & Johnson Stock (JNJ) Opened Up by 3.15% on Sep 2: Key Drivers Unveiled
• Johnson & Johnson shares rose due to defensive sector rotation into healthcare equities. • Progress on talc litigation and FDA clearances bolstered investor confidence and growth strategy. • The company posted strong quarterly earnings, raising full-year operational guidance.
Mckesson Corp Stock (MCK) Moved Up by 3.13% on Sep 1: Key Drivers Unveiled
• McKesson agreed to acquire Precision Medicine Group to expand its oncology portfolio. • The company raised its quarterly dividend payout by fifteen percent. • Annual revenue reached $403.43 billion, ranking first in the industry.
Novartis AG Stock (NVS) Moved Up by 6.54% on Sep 1: Drivers Behind the Movement
• Remibrutinib succeeded in Phase III multiple sclerosis trials, showing clinical superiority. • Novartis paused eight early-stage CAR-T trials following three patient deaths. • The company reports $56.33B annual revenue and $13.98B net profit.
Biontech SE Stock (BNTX) Closed Down by 8.37% on Aug 28: What Signal Does It Send?
• BioNTech and Genentech terminated their Phase 2 autogene cevumeran colorectal cancer trial. • The independent Data Safety Monitoring Board concluded the trial lacked clinical efficacy. • BioNTech reports $3.33B in annual revenue and a net profit of $-1.32B.
Moderna Inc's Score
Media Coverage
Analyst Rating
Moderna Inc Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
Moderna Inc Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Fidelity Management & Research Company LLC | 6.74% |
| Vanguard Capital Management, LLC | 5.76% |
| BlackRock Institutional Trust Company, N.A. | 5.30% |
| Baillie Gifford & Co. | 5.04% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 45.49% |
| Investment Advisor/Hedge Fund | 14.13% |
| Hedge Fund | 10.11% |
| Corporation | 4.56% |
Related Instruments
Popular Instruments
